Phase II trial of single agent bortezomib (VELCADE®) in patients with previously untreated multiple myeloma (MM)

被引：30

作者：

Richardson, PG

Chanan-Khan, A

Schlossman, RL

Munshi, NC

Wen, P

Briemberg, H

Kuter, D

Oaklander, AL

Lonial, S

Hassoun, H

Doss, D

Colson, K

McKenney, M

Hande, K

Koryzna, A

Stoklas, B

Lunde, L

Gorelik, S

McAlister, C

Freeman, A

Warren, D

Collins, D

Esseltine, D

Amato, A

Anderson, KC

机构：

[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Boston, MA 02115 USA

[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Emory Univ, Atlanta, GA 30322 USA

[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[7] Millennium Pharmaceut Inc, Cambridge, MA USA

来源：

BLOOD | 2004年 / 104卷 / 11期

关键词：

D O I：

10.1182/blood.V104.11.3463.3463

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

336

引用

页码：100A / 100A

页数：1